Latest Insider Transactions at Silk Road Medical Inc (SILK)
This section provides a real-time view of insider transactions for Silk Road Medical Inc (SILK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Silk Road Medical Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Silk Road Medical Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2022
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.82%
|
$30,000
$1.6 P/Share
|
|
Jul 08
2022
|
Elizabeth H Weatherman |
SELL
Open market or private sale
|
Direct |
10,000
-4.09%
|
$410,000
$41.91 P/Share
|
|
Jul 05
2022
|
Andrew S. Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-0.07%
|
$2,553
$37.8 P/Share
|
|
Jun 09
2022
|
Elizabeth H Weatherman |
BUY
Grant, award, or other acquisition
|
Direct |
846
+0.34%
|
-
|
|
Jun 09
2022
|
Kevin J. Ballinger |
BUY
Grant, award, or other acquisition
|
Direct |
846
+37.4%
|
-
|
|
Jun 09
2022
|
Rick D Anderson |
BUY
Grant, award, or other acquisition
|
Direct |
846
+37.4%
|
-
|
|
Jun 09
2022
|
Tanisha Carino |
BUY
Grant, award, or other acquisition
|
Direct |
846
+50.0%
|
-
|
|
Jun 09
2022
|
Tony M. Chou |
BUY
Grant, award, or other acquisition
|
Direct |
846
+0.85%
|
-
|
|
Jun 09
2022
|
Jack W Lasersohn |
BUY
Grant, award, or other acquisition
|
Direct |
846
+12.03%
|
-
|
|
Jun 09
2022
|
Donald Zurbay |
BUY
Grant, award, or other acquisition
|
Direct |
846
+29.11%
|
-
|
|
May 20
2022
|
Lucas W. Buchanan COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
550
+0.22%
|
$13,200
$24.51 P/Share
|
|
May 20
2022
|
Erica J. Rogers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
550
+0.22%
|
$13,200
$24.51 P/Share
|
|
May 20
2022
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
550
+0.52%
|
$13,200
$24.51 P/Share
|
|
Apr 11
2022
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-10.88%
|
$1,290,000
$43.37 P/Share
|
|
Apr 11
2022
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.82%
|
$30,000
$1.6 P/Share
|
|
Mar 03
2022
|
Erica J. Rogers President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,100
-1.25%
|
$108,500
$35.72 P/Share
|
|
Mar 03
2022
|
Erica J. Rogers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,570
+18.88%
|
-
|
|
Mar 03
2022
|
Andrew S. Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,295
-1.23%
|
$46,620
$36.06 P/Share
|
|
Mar 03
2022
|
Lucas W. Buchanan COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,527
-0.61%
|
$54,972
$36.24 P/Share
|
|
Mar 03
2022
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-0.59%
|
$28,908
$36.6 P/Share
|
|
Mar 02
2022
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,820
+24.89%
|
-
|
|
Mar 02
2022
|
Lucas W. Buchanan COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
65,280
+12.24%
|
-
|
|
Mar 02
2022
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
BUY
Grant, award, or other acquisition
|
Direct |
17,950
+11.71%
|
-
|
|
Jan 12
2022
|
Lucas W. Buchanan COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.63%
|
$5,000
$1.6 P/Share
|
|
Jan 11
2022
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-7.03%
|
$410,000
$41.88 P/Share
|
|
Jan 11
2022
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.57%
|
$10,000
$1.6 P/Share
|
|
Dec 13
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-7.03%
|
$400,000
$40.95 P/Share
|
|
Dec 13
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.57%
|
$10,000
$1.6 P/Share
|
|
Nov 30
2021
|
Erica J. Rogers President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+1.86%
|
$102,500
$41.3 P/Share
|
|
Nov 16
2021
|
Lucas W. Buchanan COO & CFO |
SELL
Open market or private sale
|
Direct |
10,000
-5.26%
|
$500,000
$50.32 P/Share
|
|
Nov 16
2021
|
Lucas W. Buchanan COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.0%
|
$40,000
$4.73 P/Share
|
|
Nov 11
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
18,095
-4.33%
|
$904,750
$50.58 P/Share
|
|
Nov 11
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,738
+5.29%
|
$15,738
$1.53 P/Share
|
|
Nov 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,805
-1.32%
|
$288,300
$60.96 P/Share
|
|
Nov 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,805
+1.28%
|
$105,710
$22.77 P/Share
|
|
Oct 27
2021
|
Lucas W. Buchanan COO & CFO |
SELL
Open market or private sale
|
Direct |
10,000
-2.7%
|
$590,000
$59.39 P/Share
|
|
Oct 27
2021
|
Lucas W. Buchanan COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.63%
|
$120,000
$12.15 P/Share
|
|
Oct 11
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-7.69%
|
$605,000
$55.73 P/Share
|
|
Oct 11
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+7.14%
|
$11,000
$1.6 P/Share
|
|
Oct 01
2021
|
Lucas W. Buchanan COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,658
-1.46%
|
$146,190
$55.24 P/Share
|
|
Oct 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,324
-4.3%
|
$335,172
$53.9 P/Share
|
|
Oct 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,324
+4.12%
|
$25,296
$4.73 P/Share
|
|
Sep 28
2021
|
Lucas W. Buchanan COO & CFO |
SELL
Open market or private sale
|
Direct |
10,000
-5.19%
|
$540,000
$54.86 P/Share
|
|
Sep 28
2021
|
Lucas W. Buchanan COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.93%
|
$120,000
$12.15 P/Share
|
|
Sep 13
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-7.69%
|
$627,000
$57.32 P/Share
|
|
Sep 13
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+7.14%
|
$11,000
$1.6 P/Share
|
|
Sep 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,481
-2.16%
|
$382,379
$59.52 P/Share
|
|
Sep 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,324
+2.65%
|
$31,620
$5.19 P/Share
|
|
Aug 27
2021
|
Lucas W. Buchanan COO & CFO |
SELL
Open market or private sale
|
Direct |
10,000
-2.63%
|
$540,000
$54.38 P/Share
|
|
Aug 27
2021
|
Lucas W. Buchanan COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,847
+2.95%
|
$70,164
$12.15 P/Share
|